On August 28, 2019 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, reported that Pascal Touchon, the Company’s President and Chief Executive Officer, will participate in a panel titled "Up and Comers in the Cell Therapy Space" at Citi 14th Annual Biotech Conference on Wednesday, September 4, 2019 at 1:30 p.m. EDT (Press release, Atara Biotherapeutics, AUG 28, 2019, View Source [SID1234539102]). The conference will be held at the Four Seasons Hotel in Boston, MA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the panel will be available by visiting the Investors and Media section of the Atara website. An archived replay of the webcast will be available on the Company’s website for 14 days following the live panel.

On August 28, 2019 ArQule, Inc. (Nasdaq: ARQL) reported that Paolo Pucci, Chief Executive Officer, and Dr. Marc Schegerin, Chief Financial Officer, will attend Citi’s investor conference on Wednesday, September 4, 2019 at the Four Seasons Hotel in Boston, MA (Press release, ArQule, AUG 28, 2019, View Source [SID1234539068]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, Dr. Marc Schegerin will participate in the hosted panel discussion: Focusing the Laser on Precision Oncology, at 3:00 PM. The live webcast of the presentation will be available via the "Investors & Media" section of ArQule’s website, www.arqule.com, under "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation.

On August 28, 2019 ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC) reported receipt of payment of $500,000 in conjunction with the completion of a transaction for the purchase of substantially all of ImmunoCellular’s remaining assets, including its preclinical and clinical programs, technology, intellectual property and know-how (Press release, ImmunoCellular Therapeutics, AUG 28, 2019, View Source [SID1234539084]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As previously disclosed, the aggregate purchase price of the assets was $1,000,000, payable by a private biotechnology company ("Purchaser") in two payments. The first upfront payment of $500,000 was received by ImmunoCellular upon the initial closing of the asset sale transaction on May 8, 2019, and was non-refundable. The second, or continuation, payment of $500,000, which has been received, was dependent upon the satisfactory outcome of certain discussions between the Purchaser and the US Food and Drug Administration.

With the successful completion of the asset sale, ImmunoCellular plans to continue to pursue additional strategic alternatives, including a potential reverse merger with a private company seeking an expedited route to the public markets. The Company welcomes inquiries by parties interested in such a potential collaboration. As of August 23, 2019, ImmunoCellular’s balance sheet reflected a cash position of approximately $2.0 million with no debt or other liabilities other than ongoing trade payables related to its limited operations. The Company cannot guarantee that any ongoing or future strategic discussions will be successfully concluded.

On august 28, 2019 Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, reported that senior management will participate in three upcoming healthcare investor conferences (Press release, Bellicum Pharmaceuticals, AUG 28, 2019, View Source [SID1234539053]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details:

2019 Wells Fargo Securities Healthcare Conference
Date/Time: Wednesday, September 4, 2019 at 3:35 p.m. EDT
Location: Boston

Citi’s 14th Annual Biotech Conference
Date: Thursday, September 5, 2019 (one-on-one investor meetings)
Location: Boston

Ladenburg Thalmann 2019 Healthcare Conference
Date/Time: Tuesday, September 24, 2019 at 11:30 a.m. EDT
Location: New York

Live webcasts of the presentations at the Wells Fargo and Ladenburg Thalmann conferences may be accessed from the News & Events section of the Bellicum website. An archived version of each webcast will be available for replay immediately following the event.

On August 28, 2019 Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, reported its participation in the following upcoming investor conferences (Press release, Blueprint Medicines, AUG 28, 2019, View Source [SID1234539069]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Baird 2019 Global Healthcare Conference in New York, NY on Wednesday, September 4, 2019 at 3:45 p.m. ET.
Morgan Stanley Global Healthcare Conference in New York, NY on Tuesday, September 10, 2019 at 8:35 a.m. ET.
Print

A live webcast of each presentation will be available by visiting the Investors & Media section of Blueprint Medicines’ website at View Source A replay of the webcasts will be archived on Blueprint Medicines’ website for 30 days following each presentation.